(a) the supply of chemotherapy drugs such as Docetaxel, particularly in relation to:
(i) patient access to treatment,
(ii) cost to pharmacists and suppliers, and
(iii) cost to the private and public hospital systems;
(b) any long-term sustainable funding models for the supply of chemotherapy drugs, including Docetaxel; and
(c) any related matters.
For further information, contact: Committee Secretary
Senate Standing Committees on Community Affairs
PO Box 6100
Parliament House
Canberra ACT 2600
Australia